TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24]) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolite to Parent (M/P) Ratio of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ispronicline
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Drug distribution over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visible signs of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Dangerous Listening Behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response At 12 Weeks (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative abundance of Enterobacteriaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Radiographic intra-bony defect depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Waist Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cough Quality of Life Questionnaire (CQLQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intentions to take up the seasonal influenza vaccination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of mifepristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz of mifepristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of mifepristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum recurrence-free treatment interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational Latency Achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Movement Evoked Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale of Leg Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MacArthur Competence Assessment Tool for Treatment (MacCAT-T)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Everyday Compensation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Everyday Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lipid peroxidation in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Eigengene Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous and complete smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with benign ovarian disease, borderline ovarian tumors, and ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FIGO stage of ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic utility of HE4, CPH-I and IOTA in differentiating ovarian cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venipuncture acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency and amount of right-to-left shunts (RLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective response rate (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of ZD1839
Endpoint domain: Adverse events/effects
Primary endpoint: 3-Year recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Health-related Quality of Life - Mental Health Component Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduced Mood Disorder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory and oxidative stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diet adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycated Hemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Disease Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased interval of uterine contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: decreased maternal painful sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stopping the cervical change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of mucosal reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Stretch Mark Width/Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Modified Rodnan Skin Score (mRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Velocity of progression through the inflamed part of the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Faces Pain Scale-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment utilization of healthcare resources
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV seropositivity
Endpoint domain: Mortality/survival
Primary endpoint: Change in gingival condition (Modified Lobene Gingival Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival condition (Saxton and van der Ouderaa bleeding index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gingival condition (Modified Quigley and Hein plaque index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Success at time of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Anatomical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep hygiene behavior
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Objective sleep measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of skin fold height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tampa Kinesiophobia Scale (TKS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients identified as Covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of non-Covid-19 cases identified as negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Activities-specific balance confidence scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Static Posturography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary artery calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in Liebowitz Social Anxiety Scale (LSAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Snake Questionnaire (SNAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of endocrine profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacokinetic Metabolite Profile in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic Metabolite Profile in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Food Intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bayley Scales of Infant and Toddler Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anamnestic Response to HBV Vaccine (ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anamnestic Response to HBV Vaccine (CLIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in pulmonary function (FEV1 and RV/TLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Assessment of motor and process skills (AMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of Voriconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Concentrations of Voriconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of N-oxide Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Concentrations of N-oxide Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fractional Anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Post-operative Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Breast-related Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in intestinal and respiratory microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Digestive complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response of primary rectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Key Performance Indicator of Secondary Prevention of Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative risk of psychosis relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour PPBG excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number, severity and type of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Collagen-epinephrine closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epidural pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ-9) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder-7 (GAD-7) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Outcome Rating Scale (ORS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Work and Social Adjustment Scale (WSAS) score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Wound healing and eligibility for grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction or elimination of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IUD Expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: Presence of coagulase-negative Staphylococci in synovial fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: STAI-Y1 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Mean Square of Successive Differences (RMSSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR QoL (Health-Related Quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DLT (Dose-Limiting Toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Breast cancer characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Centre of pressures measurements (CoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence ratio of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of TMC207 and its M2 metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Active ROP and Unfavorable Structural Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change from Baseline Body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of Kogenate FS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Kogenate FS
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year Overall Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical survival of adhesive bridges
Endpoint domain: Mortality/survival
Primary endpoint: Variation of Weight-bearing pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematic biometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach therapeutic INR range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 in the CMAI Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Subjects Quality of Life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Caregiver Distress
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in severity of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in effect of gastrointestinal symptoms on Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Baseline Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety of IG-IMRT
Endpoint domain: Adverse events/effects
Primary endpoint: feasibility of IG-IMRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients for whom TIL cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients receiving a complete TIL-ACT infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of TIL-ACT and LDI
Endpoint domain: Adverse events/effects
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pediatric Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: oxygen uptake (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial blood flow values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxicity of Clofarabine in combination with Etoposide and Mitoxantrone
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicity of Clofarabine in combination with Etoposide and Mitoxantrone
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of Clofarabine in combination with Etoposide and Mitoxantrone
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and nature of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CHO and FAT oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detectable concentrations of hepatic Grazoprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: referrals to specialist care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pelvic and transrectal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity at distance and near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean end expiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oximetry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical outcome after plasma therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic Alcohol Effects Scale (BAES): Stimulant Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic Alcohol Effects Scale (BAES): Sedative Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Effects Questionnaire (DEQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Anaphylaxis or Other Adverse Events Suggestive of Hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Seroconversion to Anti-ecallantide Antibodies Upon Exposure to KALBITOR
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Adverse Events Related to Disordered Coagulation (Hypercoagulability and Hypocoagulability) Upon Exposure to KALBITOR
Endpoint domain: Adverse events/effects
Primary endpoint: 24 week change in baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Partial Mayo score ≤ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of stoma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Autonomic Nervous System Responsiveness (ANS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in connectivity between prefrontal cortex (PFC) and periaqueductal gray (PAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lurasidone AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Mean Days of Any Substance Use for Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean ASI Alcohol Composite Score for Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean ASI Drug Composite Score for Women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longevity of atraumatic restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of neurological events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity and sensitivity of plasma GAGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smooth muscle EMG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Inflammatory Bowel Disease Questionnaire (SIBDQ) outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: changes of cardiac left ventricular ejection fraction (LVEF, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of gastric secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of lower back flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes